Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32%

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% | Hanami

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman